CN106692193B - 用于调节外周免疫功能的方法和组合物 - Google Patents

用于调节外周免疫功能的方法和组合物 Download PDF

Info

Publication number
CN106692193B
CN106692193B CN201611001568.0A CN201611001568A CN106692193B CN 106692193 B CN106692193 B CN 106692193B CN 201611001568 A CN201611001568 A CN 201611001568A CN 106692193 B CN106692193 B CN 106692193B
Authority
CN
China
Prior art keywords
cells
cell
culture
polynucleotide
msc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201611001568.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106692193A (zh
Inventor
M·道
C·凯斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanbio Inc
Original Assignee
Sanbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanbio Inc filed Critical Sanbio Inc
Publication of CN106692193A publication Critical patent/CN106692193A/zh
Application granted granted Critical
Publication of CN106692193B publication Critical patent/CN106692193B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
CN201611001568.0A 2011-04-06 2012-04-06 用于调节外周免疫功能的方法和组合物 Active CN106692193B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161516637P 2011-04-06 2011-04-06
US61/516,637 2011-04-06
US201161541248P 2011-09-30 2011-09-30
US61/541,248 2011-09-30
CN201280024630.1A CN103547275B (zh) 2011-04-06 2012-04-06 用于调节外周免疫功能的方法和组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280024630.1A Division CN103547275B (zh) 2011-04-06 2012-04-06 用于调节外周免疫功能的方法和组合物

Publications (2)

Publication Number Publication Date
CN106692193A CN106692193A (zh) 2017-05-24
CN106692193B true CN106692193B (zh) 2021-01-05

Family

ID=47139503

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201611001568.0A Active CN106692193B (zh) 2011-04-06 2012-04-06 用于调节外周免疫功能的方法和组合物
CN201280024630.1A Active CN103547275B (zh) 2011-04-06 2012-04-06 用于调节外周免疫功能的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280024630.1A Active CN103547275B (zh) 2011-04-06 2012-04-06 用于调节外周免疫功能的方法和组合物

Country Status (6)

Country Link
US (6) US8785190B2 (enExample)
EP (1) EP2694080B1 (enExample)
JP (7) JP5932970B2 (enExample)
CN (2) CN106692193B (enExample)
CA (1) CA2832356C (enExample)
WO (1) WO2012154344A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154344A1 (en) * 2011-04-06 2012-11-15 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
JP6023218B2 (ja) 2012-01-27 2016-11-09 サンバイオ，インコーポレイティド 血管新生及び血管発生を調節するための方法及び組成物
CN109718250B (zh) 2012-05-16 2022-08-30 桑比欧公司 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
EP2906293B1 (en) 2012-10-09 2018-12-12 SanBio, Inc. Methods and compositions for treatment of retinal degeneration
ES2647494T3 (es) * 2013-03-01 2017-12-21 Apceth Gmbh & Co. Kg Protección del endotelio vascular de las reacciones citotóxicas mediadas inmunológicamente con células progenitoras humanas cd34-negativo
ES2748825T3 (es) * 2013-03-15 2020-03-18 Tigenix S A U Biomarcadores de linfocitos para determinar la respuesta clínica a la terapia celular
US20160095885A1 (en) 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
CN105985928A (zh) * 2015-02-10 2016-10-05 睿尔（天津）生物科技有限公司 一种增强间充质干细胞免疫调节能力的预处理培养方法
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
CN106148276A (zh) * 2015-04-16 2016-11-23 中国科学院上海生命科学研究院 间充质干细胞在制备治疗神经退行性疾病的药物中的应用
CN107847657A (zh) * 2015-06-15 2018-03-27 生命治疗有限公司 用于诱导抗炎反应的组合物和方法
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
US10383895B2 (en) * 2016-02-18 2019-08-20 Viera Bioscience, Inc. Stimulation of therapeutic angiogenesis by T regulatory cells
US11534496B2 (en) 2016-06-07 2022-12-27 The Brigham And Women's Hospital, Inc. Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
CN109562126A (zh) 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
WO2018125829A1 (en) 2016-12-28 2018-07-05 Sanbio, Inc. Cell delivery system and methods of operation thereof
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
WO2021075525A1 (ja) 2019-10-17 2021-04-22 テルモ株式会社 炎症性疾患を処置するための細胞培養物
CN111979186B (zh) * 2020-08-21 2022-04-08 遵义医科大学附属医院 一种快速高效体外扩增人间充质干细胞的方法及应用
CN116376828B (zh) * 2023-06-02 2023-08-11 成都云测医学生物技术有限公司 一种诱导CD4+T细胞生成Treg细胞的方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012441A1 (en) * 2001-07-25 2003-02-13 Lorantis Limited Method for detecting modulators of notch signalling
WO2009023251A1 (en) * 2007-08-15 2009-02-19 Sanbio, Inc. Methods and compositions for treating neural degeneration
CN102027118A (zh) * 2008-04-30 2011-04-20 桑比欧公司 含有dna甲基化状态改变的神经再生细胞

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5932970Y2 (ja) 1979-09-29 1984-09-14 トキナ−光学株式会社 ズ−ム式交換レンズにおける焦点距離の表示装置
JPS5993639U (ja) 1982-12-11 1984-06-25 愛知電機株式会社 撹拌装置における内容物の自動排出，投入装置
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
EP1616958A3 (en) * 1996-11-07 2006-02-08 Lorantis Limited Notch-ligands for use in immunotherapy
US6280718B1 (en) 1999-11-08 2001-08-28 Wisconsin Alumni Reasearch Foundation Hematopoietic differentiation of human pluripotent embryonic stem cells
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
US6887706B2 (en) 2001-10-03 2005-05-03 Wisconsin Alumni Research Foundation Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells
CA2475288C (en) 2002-02-06 2014-09-02 Sanbio, Inc. Method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene
KR20130062359A (ko) 2004-04-12 2013-06-12 산바이오 인코포레이티드 뉴런의 전구 세포 특징들을 나타내는 세포
EP1855700B1 (en) 2005-03-07 2013-10-30 SanBio, Inc. Use of neuronal precursor cells for treatment of central nervous system lesions
WO2008102460A1 (en) 2007-02-23 2008-08-28 Sanbio Inc. Transplantation of bone marrow stromal cell-induced neural stem cells for promoting fuctional recovery after spinal cord injury
US10702554B2 (en) 2007-12-03 2020-07-07 Sanbio, Inc. Extracellular matrix from pluripotent cells
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
US8518397B2 (en) * 2009-08-14 2013-08-27 Case Western Reserve University Notch induced natural killer cell generation and therapeutic uses
WO2012154344A1 (en) * 2011-04-06 2012-11-15 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
US20120263681A1 (en) * 2011-04-12 2012-10-18 Fujifilm Corporation Composition comprising cell and biocompatible polymer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012441A1 (en) * 2001-07-25 2003-02-13 Lorantis Limited Method for detecting modulators of notch signalling
WO2009023251A1 (en) * 2007-08-15 2009-02-19 Sanbio, Inc. Methods and compositions for treating neural degeneration
CN102027118A (zh) * 2008-04-30 2011-04-20 桑比欧公司 含有dna甲基化状态改变的神经再生细胞

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cutting Edge: Notch Signaling Induces a Distinct Cytokine Profile in Dendritic Cells That Supports T Cell-Mediated Regulation and IL-2-Dependent IL-17 Production;Laurence Bugeon等;《J Immunol.》;20081215;第181卷(第12期);摘要，第8189页左栏第1段至第8192页右栏最后1段，图3 *
mIL-10基因转染修饰骨髓间充质干/祖细胞在H-2单倍型骨髓移植aGVHD模型中的免疫生物学研究;陈峰;《中国博士学位论文全文数据库医药卫生科技辑》;20100415(第04期);摘要，第一至三部分内容 *
Notch regulates IL-10 production by T helper 1 cells;Sascha Rutz等;《Proc Natl Acad Sci》;20080304;第105卷(第9期);摘要，第3497页左栏第1段至第3502页左栏第1段 *

Also Published As

Publication number Publication date
US20240139255A1 (en) 2024-05-02
CA2832356C (en) 2017-12-19
JP2025069383A (ja) 2025-04-30
US20200113944A1 (en) 2020-04-16
JP7631387B2 (ja) 2025-02-18
JP2021001180A (ja) 2021-01-07
US10543234B2 (en) 2020-01-28
EP2694080A1 (en) 2014-02-12
JP2016135817A (ja) 2016-07-28
EP2694080B1 (en) 2018-03-14
JP6134032B2 (ja) 2017-05-24
JP2023052777A (ja) 2023-04-12
CN103547275A (zh) 2014-01-29
EP2694080A4 (en) 2014-09-03
JP2014510153A (ja) 2014-04-24
WO2012154344A1 (en) 2012-11-15
JP2019006790A (ja) 2019-01-17
JP6981934B2 (ja) 2021-12-17
US20130095084A1 (en) 2013-04-18
US8785190B2 (en) 2014-07-22
USRE46382E1 (en) 2017-05-02
JP6392926B2 (ja) 2018-09-19
US11903972B2 (en) 2024-02-20
CN106692193A (zh) 2017-05-24
CN103547275B (zh) 2016-12-28
US9655927B2 (en) 2017-05-23
JP2017149759A (ja) 2017-08-31
US20170232042A1 (en) 2017-08-17
JP7267976B2 (ja) 2023-05-02
US20140286918A1 (en) 2014-09-25
CA2832356A1 (en) 2012-11-15
JP5932970B2 (ja) 2016-06-08

Similar Documents

Publication Publication Date Title
JP7631387B2 (ja) 末梢免疫機能を調節するための方法及び組成物
CN103079579B (zh) T细胞介导的免疫病症的治疗
US20100055076A1 (en) Mesenchymal stem cell-mediated autologous dendritic cells with increased immunosuppression
AU2011274255A1 (en) Treatment of T-cell mediated immune disorders
HUE029213T2 (en) For use in treating SIRS of stromal stem cells derived from adipose tissue
HK1233517A (en) Methods and compositions for modulating peripheral immune function
HK1233517A1 (en) Methods and compositions for modulating peripheral immune function
HK1191880B (en) Methods and compositions for modulating peripheral immune function
HK1191880A (en) Methods and compositions for modulating peripheral immune function
HK1233517B (en) Methods and compositions for modulating peripheral immune function
HK1215719A1 (zh) 免疫抑制细胞及其制造和使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1233517

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant